Dose Escalation Increases Xeomin Treatment Longevity

The median duration of effect was 120 days, 180 days and 270 days for the 20-, 60- and 100-U groups, respectively.

Increasing doses of Xeomin for the glabella extends treatment longevity.
Increasing doses of Xeomin for the glabella extends treatment longevity.

A double-blind, randomized clinical trial, published in the Aesthetics Surgery Journal (June 2021), found that there is a dose-dependent relationship between incobotulinumtoxinA (Xeomin, Merz Aesthetics) and duration of effect in the glabella.

Related: Comparing Neurotoxins

Marc A Polacco, MD, et al, assessed the effects of increasing doses of incobotulinumtoxinA on the treatment duration for glabellar rhytids, by treating 38 subjects (31 female, 7 male) with moderate to severe glabellar rhytids.

Related: Modulating Expression

The subjects were randomized to receive one of three incobotulinumtoxinA doses: 20, 60 or 100 U. The authors determined effect duration by calculating the time to return to baseline for dynamic glabellar lines during maximal contraction.

The median duration of effect was 120 days, 180 days and 270 days for the 20-, 60- and 100-U groups, respectively. 

More in Injectables